NCT03387592
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of irinotecan; Patients who did not receive a first line treatment for metastatic disease with platinum compound-based regimen chemotherapy (Cisplatin/Carboplatin and Etoposide, folfox4 or Capecitabine-Oxaliplatin); Patients with uncontrolled or symptomatic brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03387592